Peel Hunt

Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, concentrating on the development and commercialization of late-stage, mineral-derived pharmaceuticals aimed at addressing significant unmet medical needs. The company’s primary focus is on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with inflammatory bowel disease, as well as chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product intended for the management of hyperphosphatemia, which is nearing the final stages of development. The company generates most of its revenue from the Feraccru segment.

Britishvolt is a developer of battery technology focused on creating low-carbon batteries to support the electrification of society. The company collaborates with strategic partners and suppliers to enhance its offerings, emphasizing the importance of sustainable energy solutions for the future. Its batteries are produced using advanced manufacturing processes, innovative modeling techniques, and recycled materials, which contribute to the advancement of sustainable transportation and the renewable energy sector. Through these efforts, Britishvolt aims to play a significant role in powering an electrified future.